Use of Cardiac Troponin in Patients with Heart Failure View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2016-10-25

AUTHORS

Wayne L. Miller

ABSTRACT

The use of cardiac troponins, and particularly with the advent of new high-sensitivity troponins, has come without adequate discussion of the proper interpretation, limitation of values, and their best use in heart failure (HF) patients. The objective of this chapter is to provide a balanced assessment of how cardiac troponins are advocated for clinical use in HF patients and areas where there are gaps in knowledge that are important for clinicians to appreciate.Although biomarkers such as troponin add to the magnitude of risk prediction, it is unclear how often their use leads to changes in treatment. The use of serial troponin testing over time would be helpful. To do this, it is necessary to take into account assay characteristics and the analytical and biological variability in addition to the ability to define normal values and effectively monitor therapy. These factors are often overlooked leading to conclusions that may not be clinically or analytically sound. An understanding of the value and limitations of troponin use is important to all clinicians who manage HF patients. If used optimally, troponin values will likely be helpful in defining when and how to effectively intervene clinically. More... »

PAGES

79-91

Book

TITLE

Cardiac Biomarkers

ISBN

978-3-319-42980-9
978-3-319-42982-3

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-42982-3_7

DOI

http://dx.doi.org/10.1007/978-3-319-42982-3_7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007671554


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miller", 
        "givenName": "Wayne L.", 
        "id": "sg:person.01166460626.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166460626.19"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2016-10-25", 
    "datePublishedReg": "2016-10-25", 
    "description": "The use of cardiac troponins, and particularly with the advent of new high-sensitivity troponins, has come without adequate discussion of the proper interpretation, limitation of values, and their best use in heart failure (HF) patients. The objective of this chapter is to provide a balanced assessment of how cardiac troponins are advocated for clinical use in HF patients and areas where there are gaps in knowledge that are important for clinicians to appreciate.Although biomarkers such as troponin add to the magnitude of risk prediction, it is unclear how often their use leads to changes in treatment. The use of serial troponin testing over time would be helpful. To do this, it is necessary to take into account assay characteristics and the analytical and biological variability in addition to the ability to define normal values and effectively monitor therapy. These factors are often overlooked leading to conclusions that may not be clinically or analytically sound. An understanding of the value and limitations of troponin use is important to all clinicians who manage HF patients. If used optimally, troponin values will likely be helpful in defining when and how to effectively intervene clinically.", 
    "editor": [
      {
        "familyName": "Maisel", 
        "givenName": "Alan S.", 
        "type": "Person"
      }, 
      {
        "familyName": "Jaffe", 
        "givenName": "Allan S.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-42982-3_7", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-42980-9", 
        "978-3-319-42982-3"
      ], 
      "name": "Cardiac Biomarkers", 
      "type": "Book"
    }, 
    "keywords": [
      "cardiac troponin", 
      "HF patients", 
      "high-sensitivity troponin", 
      "serial troponin testing", 
      "heart failure patients", 
      "troponin use", 
      "failure patients", 
      "heart failure", 
      "troponin values", 
      "troponin testing", 
      "patients", 
      "normal values", 
      "clinical use", 
      "troponin", 
      "risk prediction", 
      "clinicians", 
      "therapy", 
      "biological variability", 
      "biomarkers", 
      "treatment", 
      "adequate discussion", 
      "use", 
      "conclusion", 
      "proper interpretation", 
      "failure", 
      "assessment", 
      "factors", 
      "testing", 
      "balanced assessment", 
      "values", 
      "objective", 
      "changes", 
      "limitations", 
      "ability", 
      "advent", 
      "addition", 
      "time", 
      "knowledge", 
      "area", 
      "variability", 
      "understanding", 
      "better use", 
      "characteristics", 
      "magnitude", 
      "discussion", 
      "interpretation", 
      "chapter", 
      "gap", 
      "prediction", 
      "account", 
      "limitations of value", 
      "new high-sensitivity troponins"
    ], 
    "name": "Use of Cardiac Troponin in Patients with Heart Failure", 
    "pagination": "79-91", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007671554"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-42982-3_7"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-42982-3_7", 
      "https://app.dimensions.ai/details/publication/pub.1007671554"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-01-01T19:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/chapter/chapter_391.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-42982-3_7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-42982-3_7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-42982-3_7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-42982-3_7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-42982-3_7'


 

This table displays all metadata directly associated to this object as RDF triples.

117 TRIPLES      23 PREDICATES      76 URIs      69 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-42982-3_7 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author Nd879c7a22b6445f5b3cb66bca1daccd9
4 schema:datePublished 2016-10-25
5 schema:datePublishedReg 2016-10-25
6 schema:description The use of cardiac troponins, and particularly with the advent of new high-sensitivity troponins, has come without adequate discussion of the proper interpretation, limitation of values, and their best use in heart failure (HF) patients. The objective of this chapter is to provide a balanced assessment of how cardiac troponins are advocated for clinical use in HF patients and areas where there are gaps in knowledge that are important for clinicians to appreciate.Although biomarkers such as troponin add to the magnitude of risk prediction, it is unclear how often their use leads to changes in treatment. The use of serial troponin testing over time would be helpful. To do this, it is necessary to take into account assay characteristics and the analytical and biological variability in addition to the ability to define normal values and effectively monitor therapy. These factors are often overlooked leading to conclusions that may not be clinically or analytically sound. An understanding of the value and limitations of troponin use is important to all clinicians who manage HF patients. If used optimally, troponin values will likely be helpful in defining when and how to effectively intervene clinically.
7 schema:editor Na32f39a884e44587b75529d179ea0181
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf Nc964d813eee543028e424c2710e5a3ea
12 schema:keywords HF patients
13 ability
14 account
15 addition
16 adequate discussion
17 advent
18 area
19 assessment
20 balanced assessment
21 better use
22 biological variability
23 biomarkers
24 cardiac troponin
25 changes
26 chapter
27 characteristics
28 clinical use
29 clinicians
30 conclusion
31 discussion
32 factors
33 failure
34 failure patients
35 gap
36 heart failure
37 heart failure patients
38 high-sensitivity troponin
39 interpretation
40 knowledge
41 limitations
42 limitations of value
43 magnitude
44 new high-sensitivity troponins
45 normal values
46 objective
47 patients
48 prediction
49 proper interpretation
50 risk prediction
51 serial troponin testing
52 testing
53 therapy
54 time
55 treatment
56 troponin
57 troponin testing
58 troponin use
59 troponin values
60 understanding
61 use
62 values
63 variability
64 schema:name Use of Cardiac Troponin in Patients with Heart Failure
65 schema:pagination 79-91
66 schema:productId N678888559da541939e6903bb913f8a87
67 Nc5be831f2a00430dbc3fc46f127e5696
68 schema:publisher Nd106d162d71c4f979e8f18567428583a
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007671554
70 https://doi.org/10.1007/978-3-319-42982-3_7
71 schema:sdDatePublished 2022-01-01T19:22
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher Nf7ebda0194d34543b8a096c865af0cee
74 schema:url https://doi.org/10.1007/978-3-319-42982-3_7
75 sgo:license sg:explorer/license/
76 sgo:sdDataset chapters
77 rdf:type schema:Chapter
78 N146f358630a8460f91cb0af861d276a0 schema:familyName Jaffe
79 schema:givenName Allan S.
80 rdf:type schema:Person
81 N3bf6f780d0bf48f9a4c4bb7f9884424d schema:familyName Maisel
82 schema:givenName Alan S.
83 rdf:type schema:Person
84 N619f9548d1a44868b71ea0e1cbd802f9 rdf:first N146f358630a8460f91cb0af861d276a0
85 rdf:rest rdf:nil
86 N678888559da541939e6903bb913f8a87 schema:name dimensions_id
87 schema:value pub.1007671554
88 rdf:type schema:PropertyValue
89 Na32f39a884e44587b75529d179ea0181 rdf:first N3bf6f780d0bf48f9a4c4bb7f9884424d
90 rdf:rest N619f9548d1a44868b71ea0e1cbd802f9
91 Nc5be831f2a00430dbc3fc46f127e5696 schema:name doi
92 schema:value 10.1007/978-3-319-42982-3_7
93 rdf:type schema:PropertyValue
94 Nc964d813eee543028e424c2710e5a3ea schema:isbn 978-3-319-42980-9
95 978-3-319-42982-3
96 schema:name Cardiac Biomarkers
97 rdf:type schema:Book
98 Nd106d162d71c4f979e8f18567428583a schema:name Springer Nature
99 rdf:type schema:Organisation
100 Nd879c7a22b6445f5b3cb66bca1daccd9 rdf:first sg:person.01166460626.19
101 rdf:rest rdf:nil
102 Nf7ebda0194d34543b8a096c865af0cee schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
105 schema:name Medical and Health Sciences
106 rdf:type schema:DefinedTerm
107 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
108 schema:name Cardiorespiratory Medicine and Haematology
109 rdf:type schema:DefinedTerm
110 sg:person.01166460626.19 schema:affiliation grid-institutes:grid.66875.3a
111 schema:familyName Miller
112 schema:givenName Wayne L.
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166460626.19
114 rdf:type schema:Person
115 grid-institutes:grid.66875.3a schema:alternateName Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
116 schema:name Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
117 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...